TAP Adds Famvir To OB/GYN Portfolio
This article was originally published in The Pink Sheet Daily
Under co-promotion deal with Novartis, herpes product will join TAP’s Lupron Depot.
You may also be interested in...
FDA’s drug review center appears to have a full slate of user fee goal dates in the coming months, holding the possibility of a continued rebound.
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.
Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4